Alterity Therapeutics Data Featured at AAN Meeting
Ticker: PRNAF · Form: 6-K · Filed: Apr 17, 2024 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Apr 17, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-data, neurology, drug-development
TL;DR
Alterity's Parkinson's/MSA drug data to be shown at AAN meeting.
AI Summary
Alterity Therapeutics Limited announced on April 17, 2024, that data from its Parkinson's and Multiple System Atrophy (MSA) studies will be featured at the American Academy of Neurology (AAN) Meeting. The presentation will include data on the company's lead drug candidate, ATH434, and its potential to treat these neurodegenerative diseases.
Why It Matters
This presentation at a major neurology conference could increase visibility and investor interest in Alterity's drug candidates for Parkinson's and MSA.
Risk Assessment
Risk Level: medium — The company is a development stage enterprise, meaning its success is contingent on the future success of its drug candidates.
Key Players & Entities
- Alterity Therapeutics Limited (company) — Registrant
- ATH434 (drug_candidate) — Lead drug candidate for Parkinson's and MSA
- American Academy of Neurology (AAN) Meeting (event) — Conference where data will be featured
- Parkinson's (disease) — Condition being studied
- Multiple System Atrophy (MSA) (disease) — Condition being studied
FAQ
What specific data regarding ATH434 will be presented at the AAN Meeting?
The filing indicates that data on ATH434's potential to treat Parkinson's and MSA will be featured, but does not specify the exact data points.
When is the AAN Meeting scheduled to take place?
The filing does not specify the date of the AAN Meeting, only that the data will be featured during the month of April 2024.
What is the primary purpose of this Form 6-K filing?
This Form 6-K is a Report of Foreign Private Issuer, incorporating by reference information about Alterity Therapeutics Limited, including the featured data at the AAN Meeting.
Has Alterity Therapeutics Limited previously filed under the name Prana Biotechnology Ltd?
Yes, the filing states that the former company name was Prana Biotechnology Ltd, with a date of name change on January 5, 2001.
In which registration statements is this Form 6-K being incorporated by reference?
This Form 6-K is being incorporated by reference into Alterity's Registration Statements on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076).
Filing Stats: 196 words · 1 min read · ~1 pages · Grade level 12 · Accepted 2024-04-16 21:18:07
Filing Documents
- ea0204038-6k_alterity.htm (6-K) — 14KB
- ea020403801ex99-1_alterity.htm (EX-99.1) — 37KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001213900-24-033566.txt ( ) — 57KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 ATH - Alterity Parkinson's and MSA Data Featured at AAN Meeting 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: April 17 , 2024 2